Core Viewpoint - The stock of HeartFlow Medical-B (02160) rose over 4% ahead of its mid-year earnings announcement, with expectations of a significant reduction in net losses for the first half of 2025 compared to the previous year [1] Group 1: Earnings Announcement - HeartFlow Medical-B plans to hold a board meeting on August 28 to consider and approve its mid-year earnings [1] - The company anticipates a net loss of no more than RMB 10 million for the first half of 2025, representing a year-on-year decrease of at least 83% [1] Group 2: Revenue Drivers - The reduction in net losses is attributed to the sales of the VitaFlow Liberty transcatheter aortic valve and its delivery system in over 20 countries, resulting in more than a twofold increase in overseas revenue [1] - The commercial progress of the AnchorMan left atrial appendage occluder system and its guiding system in China has been steady, with the product obtaining CE marking and achieving commercialization in Europe during the reporting period, contributing to revenue growth [1] Group 3: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management [1] - The group's joint venture, 4C Medical Technologies, Inc., completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which generated income from the perceived sale of part of its equity [1]

Core Viewpoint - HeartFlow Medical-B (02160) is expected to report a significant reduction in net loss for the first half of 2025, projecting a loss not exceeding RMB 10 million, which represents a year-on-year decrease of no less than 83% [1] Financial Performance - The company anticipates a net loss reduction primarily due to the sales of the VitaFlow Liberty transcatheter aortic valve and its retrievable delivery system, which has been sold in over 20 countries/regions, resulting in a year-on-year revenue increase of over 200% [1] - The AnchorMan left atrial appendage occluder system and its guiding system have made steady progress in commercialization in China, achieving CE marking and commercializing in Europe during the reporting period, contributing to revenue growth [1] Operational Efficiency - The company has improved operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The joint venture 4C Medical Technologies, Inc. completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]